URGN
UroGen Pharma Ltd.
NASDAQ · USHealthcareBiotechnology
$41.12+2.21%
Price as of Jul 20, 2026
URGN growth
UroGen Pharma Ltd. growth
Reported trailing growth, forward expectations and three-year compound growth rates.
Trailing growth
Year over year
- Revenue
- +52.9%
- EBITDA
- -5.5%
- EBIT
- -0.2%
- EPS
- +13.5%
- Free cash flow
- -54.6%
- Operating cash flow
- -54.8%
Forward estimates
- Revenue
- +196.7%
- EBITDA
- —
- EPS
- +148.4%
Three-year CAGR
- Revenue
- +19.5%
- EBITDA
- -42.3%
- EBIT
- -29.0%
- Net income
- -21.0%
- EPS
- -7.8%
- Free cash flow
- -67.7%
Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.